RAFFI ASADORIAN Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for RAFFI ASADORIAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of RAFFI ASADORIAN. RAFFI ASADORIAN is Chief Financial Officer in AMYRIS, INC. ($AMRS) and Chief Financial Officer in ACELRX PHARMACEUTICALS INC ($ACRX).
Latest Insider Trading Transactions of RAFFI ASADORIAN
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 1.88 | 68,750 | 129,250 | 68,750 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 1.88 | 137,500 | 258,500 | 137,500 | |
| Mar 05 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 68,750 | 0 | 260,597 | 191.8 K to 260.6 K (+35.84 %) |
| Feb 12 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 2.63 | 9,024 | 23,733 | 183,299 | 192.3 K to 183.3 K (-4.69 %) |
| Feb 09 2021 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 2.59 | 9,414 | 24,382 | 192,323 | 201.7 K to 192.3 K (-4.67 %) |
| Feb 13 2020 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 1.71 | 7,924 | 13,550 | 188,765 | 196.7 K to 188.8 K (-4.03 %) |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 1.72 | 137,500 | 236,500 | 137,500 | |
| Feb 07 2020 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 68,750 | 0 | 196,689 | 127.9 K to 196.7 K (+53.74 %) |
| Nov 04 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.23 | 40,563 | 90,253 | 81,125 | |
| Mar 04 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 2.81 | 3,647 | 10,248 | 124,397 | 120.8 K to 124.4 K (+3.02 %) |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.51 | 137,500 | 345,125 | 137,500 | |
| Feb 13 2019 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 68,750 | 0 | 120,750 | 52 K to 120.8 K (+132.21 %) |
| Dec 17 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 2.78 | 5,000 | 13,883 | 52,000 | 47 K to 52 K (+10.64 %) |
| Nov 13 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.13 | 5,000 | 15,646 | 47,000 | 42 K to 47 K (+11.90 %) |
| Nov 13 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.13 | 5,000 | 15,646 | 47,000 | 42 K to 47 K (+11.90 %) |
| Nov 05 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.23 | 40,562 | 90,250 | 40,562 | |
| Sep 05 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 1.49 | 10,000 | 14,900 | 42,000 | 32 K to 42 K (+31.25 %) |
| Aug 06 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 2.75 | 5,000 | 13,725 | 32,000 | 27 K to 32 K (+18.52 %) |
| May 29 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.18 | 5,000 | 15,923 | 27,000 | 22 K to 27 K (+22.73 %) |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.00 | 147,500 | 295,000 | 147,500 | |
| Jan 26 2018 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 2.00 | 147,500 | 295,000 | 147,500 | |
| Nov 14 2017 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 1.94 | 5,000 | 9,711 | 12,000 | 7 K to 12 K (+71.43 %) |
| Sep 11 2017 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Buy | P | 3.24 | 7,000 | 22,705 | 7,000 | 0 to 7 K |
| Aug 17 2017 | ACRX | ACELRX PHARMACEUTI ... | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 3.00 | 220,000 | 660,000 | 220,000 | |
| Jan 04 2017 | AMRS | AMYRIS, INC. | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 0.75 | 29,186 | 21,773 | 241,648 | 270.8 K to 241.6 K (-10.78 %) |
| May 18 2016 | AMRS | AMYRIS, INC. | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 0.59 | 200,000 | 118,000 | 200,000 | |
| May 18 2016 | AMRS | AMYRIS, INC. | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 100,000 | 0 | 270,834 | 170.8 K to 270.8 K (+58.54 %) |
| Jan 05 2016 | AMRS | AMYRIS, INC. | ASADORIAN RAFFI | Chief Financial Off ... | Payment of Exercise | F | 1.62 | 29,166 | 47,249 | 170,834 | 200 K to 170.8 K (-14.58 %) |
| Jan 21 2015 | AMRS | AMYRIS, INC. | ASADORIAN RAFFI | Chief Financial Off ... | Option Exercise | A | 1.75 | 300,000 | 525,000 | 300,000 | |
| Jan 21 2015 | AMRS | AMYRIS, INC. | ASADORIAN RAFFI | Chief Financial Off ... | Grant | A | 0.00 | 200,000 | 0 | 200,000 | 0 to 200 K |
Page: 1